This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Yale Cancer Center
yalecancer.bsky.social
did:plc:2fykzdsl6dmpn5q3u2ew3gkn
Analysis of the phase 3 #KEYNOTE119 trial showed immune activity (high TILs, T-cell signals, or high mutation burden) may be predictive of response to pembrolizumab in pts with met #TNBC. #breastcancer #NPJbreastcancer
https://nature.com/articles/s41523-025-00814-y
2025-10-07T13:03:15.564Z